GENEVA--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today reported encouraging new data from an ongoing phase 1 clinical trial of XL184, a novel small molecule inhibitor of MET, VEGFR2, and RET, in patients with advanced malignancies. A total of 84 patients have been treated in the study, including 36 with medullary thyroid cancer (MTC). The results showed a disease control rate of 84% and a response rate of 55% in evaluable patients with MTC. Razelle Kurzrock, MD, Professor of Medicine and Chief of the Section on Cytokines in the Department of Bioimmunotherapy at the University of Texas M.D. Anderson Cancer Center in Houston, Texas, and Steven I. Sherman, MD, Chair and Professor, Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M.D. Anderson Cancer Center, lead investigators in the trial, presented the new data in a poster session (Abstract #379) at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, which is being held October 21-24 in Geneva, Switzerland. The poster will be available today on the Exelixis web site. Based on earlier positive data in this ongoing phase 1 clinical trial, Exelixis initiated a phase 3 trial of XL184 in MTC in July of this year. A phase1/2 trial in non-small cell lung cancer and a phase 2 trial in glioblastoma multiforme are also ongoing with XL184.
